Biomea Fusion Inc BMEA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Trading Information
- Previous Close Price
- $0.59
- Day Range
- $0.54–0.60
- 52-Week Range
- $0.54–2.24
- Bid/Ask
- $0.57 / $0.60
- Shares Outstanding
- 72.48M
- Market Cap
- $41.08M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
- Website
- https://www.biomeafusion.com
Valuation
Metric | BMEA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.39 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | BMEA |
|---|---|
Quick Ratio | 3.32 |
Current Ratio | 3.47 |
Interest Coverage | — |
Quick Ratio
BMEA
Profitability
Metric | BMEA |
|---|---|
Return on Assets (Normalized) | −87.10% |
Return on Equity (Normalized) | −227.28% |
Return on Invested Capital (Normalized) | −200.89% |
Return on Assets
BMEA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@#z&vgQ | LOCK|gYJ$ | $139B | |||
| Moderna Inc MRNA | LOCK|%Pblvp | LOCK|^Sk | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|v@m>My | LOCK|$gld$ | $94B | |||
| argenx SE ADR ARGX | LOCK|c#m<!y | LOCK|VQ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|cYc$bh | LOCK|Vm# | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|rm^@KKYg | LOCK|<@&> | $30B | |||
| Incyte Corp INCY | LOCK|#!TB%< | LOCK|ybh | $24B | |||
| BioNTech SE ADR BNTX | LOCK|>%m>^d^ | LOCK|^Fh | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|m#D<%L | LOCK|Z@@mp | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|fpVCCJr | LOCK|hY | $15B |
United States